A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy

被引：0
|
作者：
Grierson, Patrick
Wang-Gillam, Andrea
Park, Haeseong
Pedersen, Katrina
Tan, Benjamin R.
Amin, Manik A.
Suresh, Rama
Trikalinos, Nikolaos
Liu, Jingxia
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Mayo Sch Grad Med Educ, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS793
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris A.
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] PILOT-STUDY OF PALA AND 5-FU IN PATIENTS WITH ADVANCED CANCER
    OCONNELL, MJ
    POWIS, G
    RUBIN, J
    MOERTEL, CG
    CANCER TREATMENT REPORTS, 1982, 66 (01): : 77 - 80
  • [33] Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC)
    Jovtis, S
    Marantz, A
    Almira, E
    Balbiani, L
    Castilla, L
    Fein, L
    Lewi, D
    Pascón, G
    Pinkevicius, R
    Uranga, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S157 - S157
  • [34] A US multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy
    Yu, Kenneth H.
    Hendifar, Andrew
    Alese, Olatunji
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala
    Cockrum, Paul
    Bhak, Rachel
    DerSarkissian, Maral
    Nguyen, Catherine
    Duh, Mei S.
    Bahary, Nathan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 36 - 37
  • [35] Phase II study of 5-FU/LV/lrinotecan in combination with regional hyperthermia (RHT) in 5-FU/Lv refractory patients with advanced colorectal cancer
    Krych, M
    Lindner, LH
    Abele, S
    Abdel-Rahman, S
    Fahn, W
    Milani, V
    Braun, S
    Stockheim, B
    Heinemann, V
    Issels, RD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 301S - 301S
  • [36] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.
    Pelzer, Uwe
    Blanc, Jean-Frederic
    Melisi, Davide
    Cubillo, Antonio
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Wan, Yin
    Solem, Caitlyn T.
    Botteman, Marc
    Yang, Yoojung
    de Jong, Floris
    Hubner, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.
    Yu, Kenneth H.
    Hendifar, Andrew Eugene
    Alese, Olatunji B.
    Draper, Amber
    Abdelrahim, Maen
    Burns, Ethan
    Khan, Gazala Naaz
    Cockrum, Paul
    Bhak, Rachel
    DerSarkissian, Maral
    Nguyen, Catherine
    Duh, Mei Sheng
    Bahary, Nathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC - AIO-HEP-0116)
    Vogel, A.
    Wenzel, P.
    Folprecht, G.
    Schuett, P.
    Wege, H.
    Kretzschmar, A.
    Jacobasch, L.
    Ziegenhagen, N.
    Boeck, S.
    Kanzler, S.
    Mohm, J.
    Belle, S.
    Pink, D.
    Goetze, T. O.
    Goekkurt, E.
    Graeven, U.
    Schaaf, M.
    Kirstein, M.
    Saborowski, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S563 - S564
  • [39] Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer:: A phase II study
    Endlicher, E.
    Troppmann, M.
    Kullmann, A.
    Goelder, S.
    Herold, T.
    Herfarth, H.
    Grossmann, J.
    Schlottmann, K.
    Kullmann, F.
    ONCOLOGY, 2007, 72 (5-6) : 279 - 284
  • [40] Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.
    Macarulla, Teresa Mercade
    Hubner, Richard
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Yanshen, Shan
    Jameson, Gayle S.
    Lee, Kyung-Hun
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Braiteh, Fadi S.
    Cunningham, David
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Mamlouk, Khalid Kevin
    de Jong, Floris A.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345